Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey
Journal of Clinical Medicine · 16.07.2026 · 15 (14) · 5579
DOI: 10.3390/jcm15145579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.07.2026. Verfasst von Derya Demirtas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Novel agents such as brentuximab vedotin and anti-PD-1 antibodies, together with PET-adapted intensified strategies, have improved outcomes in advanced-stage classical Hodgkin lymphoma (cHL). However, their applicability remains limited in many middle-income countries because of restricted drug availability, reimbursement barriers, and toxicity concerns. Therefore, real-world data on the effectiveness of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) remains essential.
Methods
We conducted a retrospective two-center study including 95 patients with newly diagnosed cHL treated with first-line ABVD. Baseline characteristics, treatment response, progression-free survival (PFS), overall survival (OS), and mortality were compared between early-stage (I–II, n = 33) and advanced-stage (III–IV, n = 62) disease.
Results
The median age was 38 years (range, 18–73), and 69.5% were male; 65% had advanced-stage. Complete response rates were high in both early-stage (97%) and advanced-stage (95.2%) patients. Median PFS (21 vs. 23 months; p = 0.994) and OS (23 vs. 25 months; p = 0.848) were similar. Five-year OS was 84.3% for early-stage and 98% for advanced-stage patients (p = 0.292), while five-year PFS was 55.3% and 29.6% (p = 0.526). Mortality rates were comparable.
Conclusions
In this real-world cohort, first-line ABVD achieved high response rates and favorable long-term survival in advanced-stage cHL, supporting its continued use as a frontline treatment option, particularly in settings where access to novel therapies may be limited.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey.
- Department of Hematology, Elazıg Fethi Sekin City Hospital, 23280 Elazıg, Turkey.
ORCID-Profile: Derya Demirtas, Alper Koc, Nurhilal Buyukkurt, Didar Yanardag Acik
Zitieren
APA
Demirtas, D., Suyani, E., Koc, A., Aygun, B., Karabulut, Z. T., Buyukkurt, N., Unsal, C., & Acik, D. Y. (2026). Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey. Journal of Clinical Medicine, 15(14), 5579. https://doi.org/10.3390/jcm15145579
Vancouver
Demirtas D, Suyani E, Koc A, Aygun B, Karabulut ZT, Buyukkurt N, et al. Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey. Journal of Clinical Medicine. 2026;15(14):5579. doi:10.3390/jcm15145579
BibTeX
@article{Demirtas2026,
author = {Demirtas, Derya and Suyani, Elif and Koc, Alper and Aygun, Bilal and Karabulut, Zeynep Tugba and Buyukkurt, Nurhilal and Unsal, Cagatay and Acik, Didar Yanardag},
title = {Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5579},
doi = {10.3390/jcm15145579}
}
EUVIMED